Showing 5851-5860 of 10817 results for "".
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- AI Dermatology Tools Improve Patient Diagnostic Accuracy in Survey Studyhttps://practicaldermatology.com/news/ai-dermatology-tools-improve-patient-diagnostic-accuracy-in-survey-study/2486637/An AI-powered dermatology application was associated with improved consumer understanding of skin conditions, according to new research published in JAMA Dermatology. The study includ
- SEEN Launches Dermatologist-Designed Clarifying Shampoo as Scalp Care Trend Surgeshttps://practicaldermatology.com/news/seen-launches-dermatologist-designed-clarifying-shampoo-as-scalp-care-trend-surges/2486594/As scalp care continues to gain momentum within the broader beauty and wellness industry, dermatologist-founded brand SEEN is expanding its portfolio with the launch of its new Scalp Clarifying Shampoo, a product designed to bridge the gap between hair care and skin
- Icotrokinra Shows Sustained Skin Clearance Through 52 Weeks in Psoriasishttps://practicaldermatology.com/news/icotrokinra-shows-sustained-skin-clearance-through-52-weeks-in-psoriasis/2486494/New 52-week data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the sustained efficacy and safety of icotro
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- Amlitelimab Shows Efficacy Across Phase 3 AD Trialshttps://practicaldermatology.com/news/amlitelimab-shows-efficacy-across-phase-3-ad-trials/2486422/Late-breaking Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting demonstrated that amlitelimab, a nondepleting anti–OX40 ligand (OX40L) antibody, significantly improved disease severity and symptoms in patients with moderate-to-severe atopic dermatitis (AD), b
- ICONIC-TOTAL: Icotrokinra Shows Skin Clearance in Difficult-to-Treat PsO at 1 Yearhttps://practicaldermatology.com/news/iconic-total-icotrokinra-shows-skin-clearance-in-difficult-to-treat-pso-at-1-year/2484061/Icotrokinra, a novel oral IL-23 inhibitor, was associated with imporvements in plaque psoriasis in difficult-to-treat areas of the body, according to new data presented at 2025 Fall Clinical Dermatology Conference in Las Vegas.
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia